AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$ISRG

Brosius Mark sold $17K of ISRG

Brosius Mark (EVP & Chief Mfg and Supply Cha) sold 48 shares of INTUITIVE SURGICAL INC (ISRG) at an average of $357.10 ($347.66–$365.79) across 2 trades over 2026-09-10 to 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brosius Mark
Published Sep 11, 2026, 10:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 10:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ISRG
Neutral
high confidence
Mentioned
$ISRG
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGNeutralLow
01

Why it matters

The disclosed sale is small and pre‑arranged, offering little new insight for traders.

02

Market read

Routine insider sell with negligible market impact.

03

What to watch

The sale was executed under a pre‑arranged 10b5‑1 plan, reducing the likelihood of information‑based motives.

Relevance 2/10Novelty 4/10Timing: filing date 2026‑09‑11

Background

SEC Form 4 filings disclose insider transactions; they are primary sources for insider activity.

Company-level read

Ticker impact

$ISRGNeutralHigh confidence
Context

Mark Brosius, EVP & Chief Mfg and Supply Chain at Intuitive Surgical, sold 48 shares for $17,140 via a 10b5‑1 plan.

Expected impact

No material price impact expected.

Evidence & confidence

The sale size is small relative to market cap and disclosed via a routine 10b5‑1 plan.

Market effects

Sector

None; the transaction is company‑specific and does not affect the broader medical device sector.

Regional

None; limited to US investors tracking insider activity.

Global

Minimal.

Counterpoint

What could challenge this read

If the insider had a larger stake, the sale could signal concerns, but at this scale it is routine.

Key entities

  • Company
    Intuitive Surgical Inc.

    Medical device maker (ticker ISRG).

  • Executive
    Mark Brosius

    EVP & Chief Manufacturing and Supply Chain at Intuitive Surgical.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ISRG insider trading history →

Related articles

SEP 15
$ISRGHighAI 8/10

Intuitive receives CE mark for transvaginal use of da Vinci SP system

Intuitive Surgical (ISRG) received CE mark approval for its da Vinci SP system for transvaginal gynecological procedures in Europe, expanding its use in women's health. The system, already approved for other surgeries, allows single-incision operations, potentially improving recovery and outcomes. It is also approved in the US, Japan, and Korea.

yahoo.com2 min
SEP 14
$ISRGHigh

Intuitive announces expanded indication for da Vinci SP in Europe

Intuitive (ISRG) received CE mark approval for transvaginal gynecologic procedures using the da Vinci SP system in Europe, expanding its applications. The approval allows for less invasive options and potentially better recovery experiences. The system is already approved in the US, Japan, and Korea for various procedures.

prnewswire.com2 min
SEP 10
$IARTMedAI 8/10

Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Integra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.

yahoo.com3 min
SEP 9
$ISRGMed

ISRG Stock Trading at its Cheapest in 10 Years: Should You Buy Now?

Intuitive Surgical (ISRG) trades at its lowest valuation in a decade, with a forward P/E of 30.26x, below its 10-year median. Despite a 40% decline, Q2 2026 revenue grew 19% to $2.89B, and EPS rose 28%. Management maintained 2026 da Vinci procedure growth forecast at 13.5-15.5%, citing international growth but noting U.S. and China uncertainties. ISRG's product pipeline includes da Vinci 5 and Ion systems, with innovations like SP procedures up 61%. Shares lag industry and sector, down 15% in 3

theglobeandmail.com3 min